TrialGynecologic oncology2010

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Ernest S Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.